The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
An Open Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Vector Vaccine Against Influenza A in Healthy Volunteers in 3 Groups With a Dose Escalation
Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
A PHASE1 clinical study on Influenza A and Influenza A Virus Infection, this trial is completed. The trial is conducted by Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation and has accumulated 8 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .